Common Stock, $0.0001 par value per share
- Symbol
- ALMR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Alamar Biosciences, Inc.
ALMRNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. Alamar Biosciences, Inc. (the “Company”) is deeply saddened to report that Ian Ratcliffe, a member of the Company’s board of directors (the “Board”), passed away on July 5, 2026. The Company’s management and Board extend their sincerest condolences to Mr. Ratcliffe’s family. Mr. Ratcliffe served as an independent director on the Board since February 2024.…
Company context
We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics.
Current securities
Registered securities in this filing
Alamar Biosciences, Inc. · 8-K · Filed 2026-07-15
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
Alamar Biosciences, Inc. (the “Company”) is deeply saddened to report that Ian Ratcliffe, a member of the Company’s board of directors (the “Board”), passed away on July 5, 2026. The Company’s management and Board extend their sincerest condolences to Mr. Ratcliffe’s family. Mr. Ratcliffe served as an independent director on the Board since February 2024. The Company is extremely grateful for Mr. Ratcliffe’s dedication and service to the Company.
Following Mr. Ratcliffe’s passing, the Board decreased the number of authorized directors constituting the full Board to five and appointed Nicholas Naclerio, Ph. D., to the Audit Committee of the Board.